Milestone Pharmaceuticals
MIST
79 hedge funds and large institutions have $53.6M invested in Milestone Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 28 funds opening new positions, 21 increasing their positions, 9 reducing their positions, and 9 closing their positions.
211% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 9
133% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 9
30% more funds holding
Funds holding: 61 → 79 (+18)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
9.06% less ownership
Funds ownership: 40.17% → 31.11% (-9.1%)
22% less capital invested
Capital invested by funds: $68.3M → $53.6M (-$14.7M)
73% less call options, than puts
Call options by funds: $667K | Put options by funds: $2.47M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.65M |
| 2 |
Two Sigma Investments
New York
|
+$1.83M |
| 3 |
Jane Street
New York
|
+$1.47M |
| 4 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$1.43M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$8.97M |
| 2 |
O
OrbiMed
New York
|
-$6.44M |
| 3 |
Morgan Stanley
New York
|
-$4.71M |
| 4 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
-$2.86M |
| 5 |
PBM
Propel Bio Management
Los Angeles,
California
|
-$2.17M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MWA
76
Medallion Wealth Advisors
Farmington,
Connecticut
| $687 | +$732 | +340 | New |
|
|
RWM
77
Rialto Wealth Management
Syracuse,
New York
| $606 | +$646 | +300 | New |
|
|
KCM
78
Key Capital Management
Hendersonville, Tn 37075,
Tennessee
| $428 | +$457 | +212 | New |
|
|
SS
79
SBI Securities
Tokyo,
Japan
| $12 | – | – | – |
|
|
O
80
OrbiMed
New York
| – | -$6.44M | -3,221,828 | Closed |
|
|
SFM
81
Sphera Funds Management
Tel Aviv,
Israel
| – | -$1.64M | -820,000 | Closed |
|
|
AAA
82
Affinity Asset Advisors
New York
| – | -$1.33M | -666,666 | Closed |
|
83
Goldman Sachs
New York
| – | -$713K | -356,567 | Closed |
|
|
QC
84
Quadrature Capital
London,
United Kingdom
| – | -$448K | -223,470 | Closed |
|
|
HF
85
HRT Financial
New York
| – | -$277K | -138,812 | Closed |
|
86
Simplex Trading
Chicago,
Illinois
| – | -$133K | -66,920 | Closed |
|
|
SC
87
Sapient Capital
Indianapolis,
Indiana
| – | -$24.8K | -12,200 | Closed |
|
|
WANY
88
Wealthspire Advisors (New York)
New York
| – | -$2.26K | -1,129 | Closed |
|
MIST Hedge Fund Activity: Q4 2025 in Review
79 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q4 2025, worth a combined $53.6M — down 22% from $68.3M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new MIST positions and 9 closed out — a net gain of 19 holders — while 21 added to existing stakes and 9 trimmed.
The largest buyer was Marshall Wace, adding an estimated $2.65M. The largest seller was Adage Capital Partners, cutting an estimated $8.97M.
- 79 institutional investors held Milestone Pharmaceuticals (MIST) as of Q4 2025, up from 61 in Q3 2025.
- Funds reported $53.6M of Milestone Pharmaceuticals stock for Q4 2025, down 22% quarter-over-quarter.
- 28 funds opened new Milestone Pharmaceuticals positions in Q4 2025 and 9 closed out, a net change of +19 holders.
- The largest Milestone Pharmaceuticals buyer in Q4 2025 was Marshall Wace, an estimated $2.65M added.
- The largest Milestone Pharmaceuticals seller in Q4 2025 was Adage Capital Partners, an estimated $8.97M sold.
Based on aggregated 13F filings for Q4 2025.